MY202135A - Uses of neuroactive compounds - Google Patents
Uses of neuroactive compoundsInfo
- Publication number
- MY202135A MY202135A MYPI2017000507A MYPI2017000507A MY202135A MY 202135 A MY202135 A MY 202135A MY PI2017000507 A MYPI2017000507 A MY PI2017000507A MY PI2017000507 A MYPI2017000507 A MY PI2017000507A MY 202135 A MY202135 A MY 202135A
- Authority
- MY
- Malaysia
- Prior art keywords
- neuroactive compounds
- sterol
- subject
- disorder
- lemli
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003432 sterols Chemical class 0.000 abstract 2
- 235000003702 sterols Nutrition 0.000 abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY202135A true MY202135A (en) | 2024-04-05 |
Family
ID=55653736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017000507A MY202135A (en) | 2014-10-07 | 2015-10-07 | Uses of neuroactive compounds |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (enExample) |
| EP (1) | EP3204011A4 (enExample) |
| JP (3) | JP2017530982A (enExample) |
| KR (1) | KR20170065637A (enExample) |
| CN (2) | CN107405352A (enExample) |
| AU (2) | AU2015330906A1 (enExample) |
| BR (1) | BR112017007053A2 (enExample) |
| CA (1) | CA2963938C (enExample) |
| IL (2) | IL292465B2 (enExample) |
| MX (2) | MX388694B (enExample) |
| MY (1) | MY202135A (enExample) |
| PE (1) | PE20170907A1 (enExample) |
| PH (1) | PH12017500639A1 (enExample) |
| RU (1) | RU2764702C2 (enExample) |
| SG (2) | SG11201702799UA (enExample) |
| WO (1) | WO2016057713A1 (enExample) |
| ZA (1) | ZA201702545B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SMT202200094T1 (it) | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| SMT202100476T1 (it) | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| WO2018026781A1 (en) * | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN110267966B (zh) * | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) * | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010088414A2 (en) * | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP2841067A4 (en) * | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| AU2014212487C1 (en) * | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| RU2021111681A (ru) | 2013-03-13 | 2021-05-11 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| WO2015195967A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) * | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
-
2015
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY202135A (en) | Uses of neuroactive compounds | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12014502704B1 (en) | Compounds and compositions for modulating egfr activity | |
| MX367420B (es) | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. | |
| MX2020003224A (es) | Moduladores de receptor nuclear. | |
| MY195289A (en) | Anti IL-36R Antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| IN2014CN02616A (enExample) | ||
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| PH12013500529A1 (en) | Methods and compositions for treating lung cancer | |
| MX2015005858A (es) | Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol. | |
| MX358499B (es) | Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). | |
| WO2013138568A8 (en) | Liver x receptor modulators | |
| MX356933B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| MX2015005720A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40). | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| IN2014DN07636A (enExample) | ||
| EA201491894A1 (ru) | Способы лечения непереносимости лактозы | |
| AU2011322715A8 (en) | Treatment of MeCP2-associated disorders | |
| WO2014145897A3 (en) | Immunotherapy system and method thereof | |
| TW201613878A (en) | Pyrazine GPR40 agonists for the treatment of type II diabetes | |
| IN2014KN02993A (enExample) | ||
| MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. |